SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC
Clinical trial NCT05438108 · UNKNOWN
Trial details
- NCT number
- NCT05438108
- Sponsor
- Huazhong University of Science and Technology
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-01
- Primary completion
- 2023-01-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.